MyFinsight
Home
Blog
About
Issuance of common stock
related to private...
$2,739,973
Net cash provided by
financing activities
$2,739,973
(249.60%↑ Y/Y)
Net increase
(decrease) in cash and cash...
-$4,581,352
(-156.02%↓ Y/Y)
Canceled cashflow
$2,739,973
Stock-based compensation
expense
$213,752
(-85.31%↓ Y/Y)
Depreciation and
amortization
$201,840
(-64.70%↓ Y/Y)
Loss from equity
method investment
-$52,157
(-243.05%↓ Y/Y)
Inventory
-$35,781
(57.10%↑ Y/Y)
Accounts receivable
-$33,887
(-152.01%↓ Y/Y)
Change in fair value of
acquisition contingencies
-$29,171
(-104.01%↓ Y/Y)
Deferred revenue
$28,044
(460.88%↑ Y/Y)
Non-cash lease expense
$2,380
(218.82%↑ Y/Y)
Net cash used in
operating activities
-$7,153,044
(58.00%↑ Y/Y)
Canceled cashflow
$597,012
Net cash (used in)
provided by investing...
-$168,281
(-100.69%↓ Y/Y)
Net loss
-$6,283,786
(58.83%↑ Y/Y)
Accounts payable,
accrued expenses and...
-$1,405,043
(56.27%↑ Y/Y)
Inventory obsolescence
recoveries
-$31,331
(67.12%↑ Y/Y)
Prepaid expenses and
other assets
$26,289
(103.81%↑ Y/Y)
Provision for credit
losses
-$3,607
Investment in joint
ventures
$150,000
Purchases of property and
equipment
$18,281
(-96.29%↓ Y/Y)
Back
Back
Cash Flow
Co-Diagnostics, Inc. (CODX)
Co-Diagnostics, Inc. (CODX)
source: myfinsight.com